Montrouge, France

Renato Monteiro

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Renato Monteiro

Introduction

Renato Monteiro is a notable inventor based in Montrouge, France. He has made significant contributions to the field of medical research, particularly in the development of antibodies for therapeutic applications. With a total of two patents to his name, Monteiro's work has the potential to impact the treatment of various diseases.

Latest Patents

Monteiro's latest patents include an anti-TfR antibody, which relates to the monoclonal antibody A24 directed against the transferrin receptor. This antibody is particularly useful as an antiproliferative agent. Another significant invention is a monovalent ligand of the FcαRI receptor, which serves as an anti-inflammatory agent. This invention focuses on the use of a monovalent antibody fragment directed against the EC2 domain of the FcαRI receptor for the treatment of inflammatory diseases.

Career Highlights

Throughout his career, Renato Monteiro has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and the Centre National de la Recherche Scientifique. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Monteiro has collaborated with notable colleagues, including Olivier Hermine and Ivan Moura. These partnerships have likely enriched his research and expanded the impact of his inventions.

Conclusion

Renato Monteiro's innovative work in the field of antibody development showcases his dedication to advancing medical science. His patents reflect a commitment to addressing critical health challenges through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…